Tags: US | MED | FDA | Hemophilia Treatment

FDA OKs New Therapy for Hemophilia

FDA OKs New Therapy for Hemophilia
(Copyright DPC)

Friday, 17 November 2017 09:56 AM

U.S. regulators have approved the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia, an inherited blood-clotting disorder.

The Food and Drug Administration on Thursday approved Hemlibra (hem-LEE'-bruh), a weekly injection for hemophilia A patients who have developed resistance to standard medicines.

Genentech, the drug's developer, says the list price will be about $482,000 for the first year and slightly less after that.

Genentech, a subsidiary of Swiss drugmaker Roche, says that's half the cost of the only other option for patients with this resistance. That treatment requires an IV drip several times a week.

Hemophilia mostly affects males.

© Copyright 2018 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

   
1Like our page
2Share
Health-News
The FDA has approved the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia.
US, MED, FDA, Hemophilia Treatment
106
2017-56-17
Friday, 17 November 2017 09:56 AM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved